Novan (NOVN) Competitors

Novan (NASDAQ:NOVN) and Agile Therapeutics (NASDAQ:AGRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

Which has more volatility & risk, NOVN or AGRX?

Novan has a beta of -0.06, indicating that its stock price is 106% less volatile than the S&P 500. Comparatively, Agile Therapeutics has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.

Which has stronger valuation and earnings, NOVN or AGRX?

Agile Therapeutics has lower revenue, but higher earnings than Novan. Agile Therapeutics is trading at a lower price-to-earnings ratio than Novan, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novan	$24.71M	0.00	-$31.31M	-$1.32	0.00
Agile Therapeutics	$19.59M	0.13	-$14.47M	-$9.84	-0.04

Do analysts recommend NOVN or AGRX?

Agile Therapeutics has a consensus target price of $8.50, indicating a potential upside of 2,136.84%. Given Agile Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Agile Therapeutics is more favorable than Novan.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novan	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Agile Therapeutics	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Does the media favor NOVN or AGRX?

In the previous week, Novan and Novan both had 1 articles in the media. Novan's average media sentiment score of 0.00 equaled Agile Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novan	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Agile Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community prefer NOVN or AGRX?

Agile Therapeutics received 185 more outperform votes than Novan when rated by MarketBeat users. Likewise, 67.84% of users gave Agile Therapeutics an outperform vote while only 56.50% of users gave Novan an outperform vote.

Company	Underperform	Outperform
Novan	Outperform Votes 239 56.50%	Underperform Votes 184 43.50%
Agile Therapeutics	Outperform Votes 424 67.84%	Underperform Votes 201 32.16%

Do institutionals and insiders hold more shares of NOVN or AGRX?

14.5% of Novan shares are owned by institutional investors. Comparatively, 10.9% of Agile Therapeutics shares are owned by institutional investors. 1.3% of Novan shares are owned by insiders. Comparatively, 0.5% of Agile Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Is NOVN or AGRX more profitable?

Agile Therapeutics has a net margin of -73.83% compared to Novan's net margin of -128.61%. Agile Therapeutics' return on equity of 0.00% beat Novan's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novan	-128.61%	-700.28%	-39.58%
Agile Therapeutics	-73.83%	N/A	-179.07%

Summary

Agile Therapeutics beats Novan on 10 of the 16 factors compared between the two stocks.